Prader-Willi Syndrome Pipeline Assessment (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Prader-Willi Syndrome Pipeline Assessment (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

“Delveinsight Business Research LLP”
As per DelveInsight’s assessment, about 18+ key pharma and biotech companies are working on 18+ pipeline drugs in the Prader-Willi Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Prader-Willi Syndrome therapeutics market is anticipated to evolve immensely in the coming years, owing to the rise in the number of cases of Prader-Willi Syndrome and the expected launch of the pipeline therapies. The Prader-Willi Syndrome (PWS) pipeline possesses potential drugs in mid-and late-stage developments. Key players like Soleno Therapeutics, Levo Therapeutics, and others hold the potential to create a significant positive shift in the Prader-Willi Syndrome (PWS) market dynamics and treatment outlook. 

Prader-Willi Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Prader-Willi Syndrome Market. 

The Prader-Willi Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases.  The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Prader-Willi Syndrome Pipeline Analysis

Prader-Willi Syndrome Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Prader-Willi Syndrome and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Prader-Willi Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Prader-Willi Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

  • Potassium channel agonists

  • Iron chelating agents

  • Serotonin uptake inhibitors

  • Synaptic transmission modulators

  • G protein-coupled receptor agonists

  • Histamine H3 receptor inverse agonists

  • Cannabinoid receptor modulators

  • Ghrelin receptor antagonists

  • Gastric inhibitory polypeptide receptor antagonists

Learn How the Ongoing Clinical & Commercial Activities will Affect the Prader-Willi Syndrome Therapeutic Segment @

https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

Prader-Willi Syndrome Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Prader-Willi Syndrome. Currently, Soleno Therapeutics is leading the therapeutics market with its Prader-Willi Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Prader-Willi Syndrome Therapeutics Market Include:

  • ConSynance Therapeutics

  • GLWL Research

  • Helsinn

  • Inversago Pharma

  • Larimar Therapeutics

  • Levo Therapeutics

  • LG Life Sciences

  • Neuren Pharmaceuticals

  • OptiNose

  • Radius Health

  • Rhythm

  • Saniona

  • Soleno Therapeutics

  • Tonix Pharmaceuticals

And Many Others

Prader-Willi Syndrome Emerging and Marketed Drugs Covered in the Report Include:

  • Diazoxide Choline Controlled-Release (DCCR): Soleno Therapeutics Inc.

  • Intranasal carbetocin (LV-101): Levo Therapeutics

  • GENOTROPIN (somatropin): Pfizer

  • OMNITROPE: Sandoz

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Prader-Willi Syndrome Current Treatment Patterns

4. Prader-Willi Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Prader-Willi Syndrome Late Stage Products (Phase-III)

7. Prader-Willi Syndrome Mid-Stage Products (Phase-II)

8. Prader-Willi Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Prader-Willi Syndrome Discontinued Products

13. Prader-Willi Syndrome Product Profiles

14. Key Companies in the Prader-Willi Syndrome Market

15. Key Products in the Prader-Willi Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Prader-Willi Syndrome Unmet Needs

18. Prader-Willi Syndrome Future Perspectives

19. Prader-Willi Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/